Sorcero ·21 November 2025·3 outlets
Sorcero raised a $42.5 million Series B led by NewSpring Capital
NewSpring Capital led a $42.5 million Series B to expand the platform across life sciences. Medical affairs, safety and scientific communications teams at large pharmaceutical companies use its medically tuned AI to surface evidence and capture insights.
We backed Sorcero because medical affairs has had few good tools for the volume of evidence it is expected to read, and accuracy and traceability are not optional in that industry. Working with a meaningful share of the largest global pharma companies gave us confidence that the product earns trust in a demanding market, and this round funds the expansion on top of it.
- Company
- Sorcero, www.sorcero.com
- First reported
- 21 November 2025
- Outlets
- Drug & Device World, Pulse 2.0, PR Newswire
Who covered it
- Sorcero raises $42.5 million for AI adoption in life sciencesDrug & Device World, 24 November 2025
- Sorcero: $42.5 Million Series B Raised To Advance Expansion Of Its Life Sciences AI PlatformPulse 2.0, 23 November 2025
- Sorcero Secures $42.5M Series B Financing Led by NewSpring Capital to Scale Its AI Platform, Accelerate Expansion Across Life SciencesPR Newswire, 21 November 2025
Headlines and links belong to the publications that wrote them. Everything above this line is ours.